Psoriasis and psychiatric comorbidity


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

This article is for review only. Psoriasis is a chronic disease that affects the quality of life of patients. This disease is associated with an increased risk of in outpatient settings. It is critically important to understand the impact of this disease on mental health and to identify risk factors that can help identify patients who are predisposed to mental illness. By identifying psoriatic patients at high risk of psychiatric pathology, dermatologists can work for optimal interdisciplinary treatment of the disease and, thus, help to alleviate the associated psychiatric symptoms.

Full Text

Restricted Access

About the authors

L. S Kruglova

Central State Medical Academy

A. V Pushkina

Central State Medical Academy

Email: anyasawina@gmail.com

A. A Khotko

Clinical Dermatovenerologic Dispensary

References

  1. Menter A., Gottlieb A., Feldman S.R., et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-50. Doi: 10.1016/j. jaad.2008.02.039.
  2. Kumar S., Kachhawha D., Das Koolwal G., et al. Psychiatric morbidity in psoriasis patients: a pilot study. Indian J Dermatol Venereol Leprol. 2011;77:625. doi: 10.4103/0378-6323.84074.
  3. Kimball A.B., Guerin A., Tsaneva M., et al. Economic burden of comorbidities in patients with psoriasis is substantial. J Eur Acad Dermatol Venereol. 2011;25(2):157-63. doi: 10.1111/j.1468-3083.2010.03730.x.
  4. Dauden E, Puig L., Ferrandiz C., et al. Consensus document on the evaluation and treatment of moderate-to-severe psoriasis: Psoriasis Group of the Spanish Academy of Dermatology and Venereology. J Eur Acad Dermatol Venereol. 2016;30(2):1-18. doi: 10.1111/jdv.l3542.
  5. Palijan T.Z., Kovacevic D., Koic E., et al. The impact of psoriasis on the quality of life and psychological characteristics of persons suffering from psoriasis. CollAntropol. 2011;35(2):81-5.
  6. Richards H.L., Fortune D.G., Griffiths C.E., Main C.J. The contribution of perceptions of stigmatisation to disability in patients with psoriasis. J Psychosom Res. 2001;50(1):11-5. doi: 10.1016/s0022-3999(00)00210-5.
  7. Evers A.W, Verhoeven E.W., Kraaimaat F.W., et al. How stress gets under the skin: cortisol and stress reactivity in psoriasis. Br J Dermatol. 2010;163:986-91. doi: 10.1111/j.1365-2133.2010.09984.x.
  8. Moynihan J., Rieder E., Tausk F.Psychoneuroimmunology: the example of psoriasis. G Ital Dermatol Venereol. 2010;145:221-28.
  9. Hunter H.J., Griffiths C.E., Kleyn C.E. Does psychosocial stress play a role in the exacerbation of psoriasis? Br J Dermatol. 2013;169:965-74. doi: 10.1111/bjd.12478.
  10. Reich A., Hrehorow E., Szepietowski J.C. Pruritus is an important factor negatively influencing the wellbeing of psoriatic patients. Acta Derm Venereol. 2010;90:257-63. doi: 10.2340/000155550851.
  11. Heller M.M., Lee E.S., Koo J.Y. Stress as an influencing factor in psoriasis. Skin Therapy Lett. 2011;16:1-6.
  12. Jankovic S., Raznatovic M., Marinkovic J., et al. Relevance of psychosomatic factors in psoriasis: a case-control study. Acta Derm Venereol. 2009;89:364-68. doi: 10.2340/000155550669
  13. Dowlatshahi E.A., Wakkee M., Arends L.R., Nijsten T. The prevalence and odds of depressive symptoms and clinical depression in psoriasis patients: a systematic review and meta-analysis. J Invest Dermatol. 20:4;:34(6)::542-5:. doi: 10.1038/jid.2013.508.
  14. Olfson M., Marcus S.C., Druss B., et al. National trends in the outpatient treatment of depression. JAMA. 2002;287(2):203-9. Doi: 10.1001/ jama.287.2.203.
  15. Esposito M., Saraceno R., Giunta A., et al. An Italian study on psoriasis and depression. Dermatology. 2006;212(2):123-27. doi: 10.1159/000090652.
  16. Schmitt J.M., Ford D.E. Role of depression in quality of life for patients with psoriasis. Dermatology. 2007;2:5(:)::7-27. doi: 10.1159/000102029.
  17. Fleming P, Roubille C., Richer V, et al. Effect of biologics on depressive symptoms in patients with psoriasis: a systematic review. J Eur Acad Dermatol Venereol. 2015;29(6):1063-70. Doi: 10.1111/ jdv. 12909.
  18. Kurd S.K., Troxel A.B., Crits-Christoph P., Gelfand J.M. The risk of depression, anxiety, and suicidality in patients with psoriasis: a population-based cohort study. Arch Dermatol. 2010;146(8):891-95. doi: 10.1001/archdermatol.2010.186.
  19. Gupta M.A., Gupta A.K. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol. 2003;4:833-doi: 10.2165/00128071-200304120 00003.
  20. Bougueon K., Misery L. Depression and psoriasis. Ann Dermatol Venereol. 2008;135(4):254-58. doi: 10.1016/S0151-9638(08)70544-1.
  21. Martin B., Sanchez-Carazo J.L., Perez-Ferriols A., et al. Clinical experience with etanercept in the treatment of psoriasis. Actas Dermosifiliogr. 2008;99:540-45.
  22. Rieder E., Tausk F Psoriasis, a model of dermatologic psychosomatic disease: psychiatric implications and treatments. Int J Dermatol. 2012;51:12-26. doi: 10.1111/j.1365-4632.2011.05071.x.
  23. Gowda S., Goldblum O.M., McCall W.V., Feldman S.R. Factors affecting sleep quality in patients with psoriasis. J Am Acad Dermatol. 2010;63:114-23. doi: 10.1016/j.jaad.2009.07.003.
  24. Kannan S., Heller M.M., lee E.S., Koo J.Y The role of tumor necrosis factor-alpha and other cytokines in depression: what dermatologists should know. J Dermatolog Treat. 2013;24:148-52. doi: 10.3109/09546634.2011.619159.
  25. Hagforsen E., Michaёlsson K., Lundgren E., et al. Women with palmoplantar pustulosis have disturbed calcium homeostasis and a high prevalence of diabetes mellitus and psychiatric disorders: a case-control study. Acta Derm Venereol. 2005;85: 225-32. doi: 10.1080/00015550510026587.
  26. Sandyk R., Pardeshi R. Mood-dependent fluctuations in the severity of tardive dyskinesia and psoriasis vulgaris in a patient with schizoaffective disorder: possible role of melatonin. Int J Neurosci. 1990;50:215-21.
  27. Devrimci-Ozguven H., Kundakci T.N., Kumbasar H., et al. The depression, anxiety, life satisfaction and affective expression levels in psoriasis patients. J Eur Acad Dermatol Venereol. 2000;14:267-71. doi: 10.1046/j.1468-3083.2000.00085.x.
  28. Kaufman K.R. Etanercept, anticytokines and mania. Int Clin Psychopharmacol. 2005;20:239-41. doi: 10.1097/00004850-200507000-00008
  29. Demirhan O., Demirbek B., Tunc E., et al. Identification of chromosome abnormalities in screening of a family with manic depression and psoriasis: predisposition to aneuploidy. Asian J Psychiatr. 2012;5:169-74. Doi: 10.1016/j. ajp.2012.02.005.
  30. Basavaraj K.H., Navya M.A., Rashmi R. Stress and quality of life in psoriasis: an update. Int J Dermatol. 2011;50:783-92. doi: 10.1111/j.1365-4632.2010.04844.x.
  31. Crosta M.L., Caldarola G., Fraietta S., et al. Psychopathology and eating disorders in patients with psoriasis. G Ital Dermatol Venereol. 2014;149:355-61.
  32. Kotrulja L., Tadinac M., Joki-Begi N.A., Gregurek R. A multivariate analysis of clinical severity, psychological distress and psychopathological traits in psoriatic patients. Acta Derm Venereol. 2010;90:251-56. doi: 10.2340/000155550838.
  33. Yang Y.W., Lin H.C. Increased risk of psoriasis among patients with schizophrenia: a nationwide population-based study. Br J Dermatol. 2012;166:899-900. doi: 10.1111/j.1365-2133.2011.10684.x.
  34. Miyaoka T., Seno H., Inagaki T., et al. Schizophrenia associated with psoriasis vulgaris: three case reports. Schizophr Res. 2000;41:383-86.
  35. Latini A., Carducci M. Psoriasis during therapy with olanzapine. Eur J Dermatol. 2003;13:404-5.
  36. Ascari-Raccagni A., Baldari U., Rossi E., Alessandrini F. Exacerbation of chronic large plaque psoriasis associated with Olanzepine therapy. J Eur Acad Dermatol Venereol. 2000;14:315-16. doi: 10.1046/j.1468-3083.2000.00056-3.x
  37. Di Nuzzo S., Zanni M., De Panfilis G. Exacerbation of paranoid schizophrenia in a psoriatic patient after treatment with cyclosporine A but not with etanercept. J Drugs Dermatol. 2007;6: 1046-47.
  38. Callis Duffin K., Wong B., Horn E.J., Krueger G.G. Psoriatic arthritis is a strong predictor of sleep interference in patients with psoriasis. J Am Acad Dermatol. 2009;60:604-8. Doi: 10.1016/j. jaad.2008.10.059.
  39. Shutty B.G., West C., Huang K.E., et al. Sleep disturbances in psoriasis. Dermatol Online J. 2013;19:1.
  40. Picardi A., Pasquini P, Cattaruzza M.S., et al. Only limited support for a role of psychosomatic factors in psoriasis. Results from a case-control study. J Psychosom Res. 2003;55:189-96. Doi: 10.1016/ s0022-3999(02)00574-3
  41. Poikolainen K., Reunala T., Karvonen J., et al. Alcohol intake: a risk factor for psoriasis in young and middle aged men? BMJ. 1990;300:780-783. doi: 10.1136/bmj.300.6727.780.
  42. Bahmer J.A., Kuhl J., Bahmer F.A. How do personality systems interact in patients with psoriasis, atopic dermatitis and urticaria? Acta Derm Venereol. 2007;87:317-24. doi: 10.2340/000155550246.
  43. Meyer N., Viraben R., Paul C. Addictions and psoriasis: an example of the dermatologist's implication in preventive medicine? Ann Dermatol Venereol. 2008;135(4):259-62. Doi: 10.1016/ S0151-9638(08)70545-3.
  44. Naldi L., Chatenoud L., Linder D., et al. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. J Invest Dermatol. 2005;125:61-7. doi: 10.1111/j.0022-202X.2005.23681.x.
  45. Adamzik K., McAleer M.A., Kirby B. Alcohol and psoriasis: sobering thoughts. Clin Exp Dermatol. 2013;38:819-22. doi: 10.1111/ced.12013.
  46. Dediol I., Buljan M., Buljan D., et al. Association of psoriasis and alcoholism: psychodermatological issue. Psychiatr Danub. 2009;21:9-13.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies